Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)

Summary

The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients with chronic total occlusions (CTOs) undergoing successful percutaneous coronary intervention (PCI).

Timeline

Start

2022-12-15

Primary completion

2024-12-01

Completion

2025-12-01

Drugs

Indications